Dupilumab Effective for Atopic Dermatitis in Young Children
Dupilumab Shows Promise for Young Children with Eczema, Study Finds
new research suggests the drug dupilumab effectively treats moderate-to-severe atopic dermatitis (AD), commonly known as eczema, in children as young as 6 months old. The study, published in the December issue of Advances in Therapy, also found the treatment to be safe for young children, with side effects consistent with those previously observed in adults.
Led by Dr. Mark Boguniewicz of the University of Colorado School of Medicine, the study focused on the impact of other allergic conditions, known as type 2 comorbidities, on the effectiveness and safety of dupilumab in young children with AD.
The analysis included children aged 6 months to 5 years with moderate-to-severe AD. Researchers compared the outcomes of children receiving dupilumab to those receiving a placebo.
Significant improvements were observed in children receiving dupilumab, irrespective of whether they also had asthma or allergic rhinitis.
At week 16 of the study, a substantially higher percentage of children receiving dupilumab achieved an Investigator’s Global assessment (IGA) score of 0/1, indicating clear or almost clear skin. They also experienced a 75% or greater advancement in their Eczema Area and Severity Index (EASI) score, a measure of eczema severity.
The study also found promising results for children with food allergies. Significantly more children with food allergies who received dupilumab achieved an IGA score of 0/1 compared to those receiving a placebo.
Dupilumab also showed promise in reducing itch, a hallmark symptom of eczema. Significantly more children receiving dupilumab, with or without asthma, allergic rhinitis, or food allergies, experienced a significant reduction in their daily itch scores compared to those receiving a placebo.
“These results suggest that dupilumab treatment may be effective in children with or without other type 2 conditions,” the authors concluded.
The study was funded by Sanofi and Regeneron, the manufacturers of dupilumab.
Promising Treatment for Young Children with Eczema: An Interview with Dr. Mark Boguniewicz
NewsDirectory3.com: Dr. Boguniewicz, thank you for speaking with us today. Your recent study on dupilumab for young children with eczema has generated a lot of interest. Could you tell us more about its findings?
Dr. Boguniewicz: Certainly. Our study showed very promising results for dupilumab in treating moderate-to-severe atopic dermatitis, or eczema, in children as young as six months old. We found that dupilumab significantly improved skin clearance and reduced itch, regardless of whether children also had other allergic conditions like asthma or food allergies.
NewsDirectory3.com: That’s encouraging news for parents of young children struggling with eczema.Did the study also address the safety of dupilumab in this age group?
dr. Boguniewicz: Yes,safety was a key focus of our research. We found that dupilumab was generally safe and well-tolerated in young children, with side effects similar to those observed in adults.
NewsDirectory3.com: This is certainly a breakthrough in eczema treatment for young children. Can you elaborate on the significance of these findings, considering the age of the participants?
Dr. Boguniewicz: Treating eczema early in life is essential. It can significantly impact a child’s quality of life,sleep,and development. Having an effective and safe treatment option like dupilumab for very young children is a major advancement in pediatric dermatology.
NewsDirectory3.com: What are the next steps for this research?
Dr. boguniewicz: We’ll continue to monitor the long-term safety and efficacy of dupilumab in young children. Further research will also explore its impact on other aspects of their health and well-being.